title: EGFR-targeted therapy and related skin toxicity.
abstract: OBJECTIVE
  To discuss the mechanism by which epidermal growth factor receptor (EGFR)-targeted agents work, the resulting cutaneous toxicities, the pathophysiology of the unique rash associated with these agents, and the management of these skin problems.
  
  
  METHODS
  Published scientific papers, review articles, book chapters, and clinical experiences.
  
  
  CONCLUSIONS
  These new targeted agents result in unique cutaneous toxicities. Researchers and clinicians have made numerous suggestions for managing the various side effects, although there is currently no research to guide evidence-based practice.
  
  
  CONCLUSIONS
  With any new treatment option, it is imperative that nurses understand how agents work to enrich their own knowledge base, as well as have a strong foundation for patient education. It is important that nurses understand potential side effects of these agents, know of possible interventions, and participate in research to identify effective interventions.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA. 02115, USA. Linda.morse@dfci.harvard.edu
authors.forename: Linda
authors.initials: L
authors.lastname: Morse
authors.forename: Pamela
authors.initials: P
authors.lastname: Calarese
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology* / Q000628:therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration*; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced; D011799:Quinazolines / Q000627:therapeutic use; D015398:Signal Transduction; D017592:Skin Care / Q000379:methods / Q000451:nursing; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068878:Trastuzumab